GlassScriptPhysician profile
Gil M Vardi
NPI 1437173119
$105,725.21
in general payments reported to CMS, 2019-2025
53 companies · $6,026 in 2025
The $6,026 reported for 2025 was more than what 85% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,041 · 2020: $38K · 2021: $34K · 2022: $14K · 2023: $3,731 · 2024: $5,568 · 2025: $6,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $10K · Food and Beverage: $3,974 · Travel and Lodging: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $10,250.00 |
| Food and Beverage | $3,974.13 |
| Travel and Lodging | $1,101.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coala Life INC | $48,073.09 | 2020-2022 | |
| Angiodynamics, INC. | $42,784.91 | 2019-2025 | Auryon Laser System 100-120 Vac |
| Biotronik INC. | $2,414.24 | 2019 | |
| Boston Scientific Corporation | $2,011.13 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $1,715.12 | 2019-2025 | |
| Medtronic, INC. | $1,484.91 | 2021-2023 | Micra |
| Cvrx, INC. | $968.72 | 2019-2023 | Barostim Neo System |
| Cardiac Dimensions, INC. | $654.69 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $435.74 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $380.22 | 2021-2024 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $333.12 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $295.32 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $284.97 | 2019-2022 | |
| Esperion Therapeutics, INC. | $276.79 | 2020-2025 | Nexletol |
| Amgen INC. | $255.86 | 2020-2025 | Repatha, Repatha |
Show all 49 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Vardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.